According to the Centers for Disease Control, the projected number of US adults age 65+ with Alzheimer’s disease is expected to nearly double in the next 20 years. With this increase in prevalence (not to mention the increase in healthcare costs and caregiver burden) comes a more urgent need for healthcare professionals to be up-to-date on clinical developments in this area of patient care and support early detection.
Educational content on this topic is not only important for relevant specialists, but also for primary care physicians who are often on the front lines of diagnosis. The HCP engagement tactics of our Univadis platform provide valuable insight into their attitudes and behaviors around developments in the field.
For example, we found that nearly two-thirds of the respondents answered incorrectly when asked to identify which biomarkers define Alzheimer’s disease. And while this suggests an opportunity for disease-state education, it also demonstrates the audience’s strong interest in the topic, as expressed through above-average engagement rates in this content.
Similarly, when asked over 1100 of our members to identify which therapy has the highest level of evidence for treatment of mild cognitive impairment, less than half named the correct answer of “exercise training.” Geriatric specialists had highest percentage of correct responses (59%) and neurologist the lowest (37%). Almost half of PCPs answered the question correctly (47%).
Of course, Alzheimer’s disease is just one area in which there is significant opportunity to provide targeted educational content that supports HCPs’ understanding of emerging therapies and helps them identify patients who are eligible for a therapy that may slow the disease’s progression.
Through a range of editorial and sponsored content, Univadis reveals HCPs’ knowledge gaps and provides a credible, easy-to-use (even fun!) channel through which to engage them in relevant educational content that support clinical decisions.